An evidence-based approach to hormonal therapies for premenopausal women with fibroids

被引:30
作者
Lethaby, Anne E.
Vollenhoven, Beverley J. [1 ,2 ]
机构
[1] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia
[2] So Hlth, Clayton, Vic, Australia
关键词
leiomyoma; leiomyomata; uterine fibroids; hormones; gonadotrophin-releasing hormone analogues; tibolone; oestrogen; progestogen; raloxifene; tamoxifen; mifepristone; asoprisinil; progesterone receptor modulators; oestrogen receptor modulators; add-back;
D O I
10.1016/j.bpobgyn.2007.07.010
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ovarian steroids, particularly oestrogen, are important factors for fibroid growth. This has provided a rationale for the investigation of hormonal therapies for women with fibroids. This chapter will assess the role of hormonal therapies for pre-menopausal women with fibroids. A comprehensive search of MEDLINE and EMBASE was undertaken in December 2006. Twenty-nine relevant randomized controlled trials and two systematic reviews were found. The included studies assessed gonadotrophin-releasing hormone analogues (GnRHa) alone, GnRHa plus add-back (with either progestagen, tibolone, combined oestrogen and progestagen, or raloxifene) and GnRHa given for at least 3 months prior to surgery for fibroids. Two trials assessed the effects of raloxifene alone. One trial assessed the effects of low-dose mifepristone, and a pilot study assessed the role of the selective progesterone receptor modulator, asoprisinil. GnRHa reduce fibroid and uterine volume and heavy bleeding but are associated with menopausal symptoms and bone loss, which limit long-term use. There is some evidence that add-back therapy, either progestagen, tibolone, combined oestrogen and progestagen, or raloxifene, can reduce the menopausal symptoms associated with GnRHa and/or loss of bone density, but there is insufficient good-quality research to make definitive conclusions. GnRHa given for at least 3 months before fibroid surgery improve pre-operative haemoglobin concentration and haematocrit, reduce uterine and pelvic symptoms, and reduce the rate of vertical incisions during laparotomy. Women undergoing hysterectomy are more likely to have a vaginal than an abdominal procedure. Limited evidence suggests that raloxifene may be useful in older premenopausal women with lower concentrations of background oestradiol. Limited short-term evidence of two progestogenic therapies indicates that low-dose mifepristone may improve quality of life and bleeding in the short term, and asoprisinil may improve bleeding and fibroid-related symptoms. In conclusion, more research is required on the role of hormonal therapies for women with fibroids, particularly add-back options and selective oestrogen and progesterone receptor modulators. No definitive conclusions can be reached on the basis of the limited evidence found.
引用
收藏
页码:307 / 331
页数:25
相关论文
共 57 条
[1]  
Andersen J, 1998, BAILLIERE CLIN OB GY, V12, P225
[2]  
[Anonymous], COCHRANE DATABASE SY
[3]   RALOXIFENE (LY139481 HCL) PREVENTS BONE LOSS AND REDUCES SERUM-CHOLESTEROL WITHOUT CAUSING UTERINE HYPERTROPHY IN OVARIECTOMIZED RATS [J].
BLACK, LJ ;
SATO, M ;
ROWLEY, ER ;
MAGEE, DE ;
BEKELE, A ;
WILLIAMS, DC ;
CULLINAN, GJ ;
BENDELE, R ;
KAUFFMAN, RF ;
BENSCH, WR ;
FROLIK, CA ;
TERMINE, JD ;
BRYANT, HU .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (01) :63-69
[4]   Transvaginal ultrasonographic findings in the uterus and the endometrium: Low prevalence of leiomyoma in a random sample of women age 25-40 years [J].
Borgfeldt, C ;
Andolf, E .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2000, 79 (03) :202-207
[5]   Comparative study of different dosages of goserelin in size reduction of myomatous uteri [J].
Bozzini, N ;
Messina, ML ;
Borsari, R ;
Hilário, SG ;
Pinotti, JA .
JOURNAL OF THE AMERICAN ASSOCIATION OF GYNECOLOGIC LAPAROSCOPISTS, 2004, 11 (04) :462-463
[6]   Future directions in myoma research [J].
Brahma, PK ;
Martel, KM ;
Christman, GM .
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2006, 33 (01) :199-+
[7]   Two-step gonadotropin-releasing hormone agonist treatment of uterine leiomyomas: Standard-dose therapy followed by reduced-dose therapy [J].
Broekmans, FJ ;
Hompes, PGA ;
Heitbrink, MA ;
Netelenbos, CC ;
Roos, JC ;
Falke, TM ;
Schoemaker, J .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (05) :1208-1216
[8]  
BUTTRAM VC, 1981, FERTIL STERIL, V36, P433
[9]  
Caird LE, 1997, HUM REPROD, V12, P436
[10]   Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues [J].
Campo, S ;
Garcea, N .
HUMAN REPRODUCTION, 1999, 14 (01) :44-48